An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
SINGAPORE – Ketamine, the controlled drug best known ... first authorized sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their patients ...
Ketamine, the controlled drug best known as a horse tranquilliser ... Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for serious ...
SINGAPORE – Ketamine, the controlled drug best known as a horse tranquilliser ... Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for ...
Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...
most studies of ketamine in depression have relied on either intravenous or intranasal administration, the latter resulting in the approval of J&J’s Spravato (esketamine) for TRD in 2019 and for ...
Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback